Astellas Flashes Cash For Ogeda's Women's Health Drug

Astellas is spending €500m up front to acquire Belgium-based biotech Ogeda for its pipeline of women's health products, including Phase II drug candidate fezolinetant, a non-hormonal treatment for menopausal hot flashes that could be on the market within five years.